DALLAS, May 8, 2013 /PRNewswire/ -- Michael Cannizzaro, Behavioral Health Group (BHG) Chairman and Chief Executive Officer, announced that BHG treatment centers are now offering both Buprenorphine and Methadone in their medication-assisted treatment programs.
Mr. Cannizzaro said, "BHG's outpatient opioid addiction treatment centers address each patient's physical opioid addiction with either Methadone or Buprenorphine medications in combination with counseling and skill development. This expanded service offering demonstrates our commitment to helping each individual patient achieve his/her best functional level in the community."
Kelly Clark, MD, BHG Chief Medical Officer, commented, "Since most patients will be clinically appropriate for either Buprenorphine or Methadone medication, the choice of which medication each patient will try will usually be decided by the patient in consultation with his/her physician. Most patients will do well on either medication, while a few will only do well on one or the other. This additional medication option offers a choice for patients, especially those with medical conditions."
BHG's mission is to achieve positive patient outcomes by using medication-assisted treatment at the lowest possible medication dosage combined with behavioral therapy to control medical and behavioral signs of opioid addiction within an outpatient setting.
About Behavioral Health Group
Behavioral Health Group (BHG) is a leading provider of opioid addiction treatment services. BHG utilizes pharmacotherapy (maintenance and detoxification) as well as counseling to treat both the bio-chemical and psychosocial aspects of addiction. In doing so, BHG offers patients their best opportunity for a successful recovery. With 29 outpatient treatment centers across the Midwest/South/Southeast, BHG provides a critical service to thousands of individuals and their communities across the country. BHG treatment centers are accredited by The Joint Commission.
SOURCE Behavioral Health Group